Replies to post #350396 on Anavex Life Sciences Corp (AVXL)

[boi568]

I would back off leaning on a 350,000 number that includes estimates from the populations of China, India, and the Third World and stick to his U.S., Europe, and Asia numbers.

[raja48185]

even if he get a small percentage of the 350,000 world wide Rett patients.

It would be wise to be conservative when coming up with world-wide numbers for patients that can afford the drug. Focus should be on US/Canada and may be Europe for cost modeling.

Prices ranging 200K-500K per year are a hard-sell in places like Asia and Africa. (Regions where more than 60% -70% of the world's population lives)

For example, 200K USD = 15 million Indian Rupees (500K is 37.5 million Indian Rupees). I am pretty confident that even if some insurance plan in India covers 90% of the cost (which I highly doubt - the 90% ), almost none would be able to pay the remaining 10%. The only way out is to provide the drug at a cheaper rate - and that is not easy as no generic version will be available.